13 results on '"Bertolini, Irene"'
Search Results
2. Parkin ubiquitination of Kindlin-2 enables mitochondria-associated metastasis suppression
- Author
-
Yeon, Minjeong, Bertolini, Irene, Agarwal, Ekta, Ghosh, Jagadish C., Tang, Hsin-Yao, Speicher, David W., Keeney, Frederick, Sossey-Alaoui, Khalid, Pluskota, Elzbieta, Bialkowska, Katarzyna, Plow, Edward F., Languino, Lucia R., Skordalakes, Emmanuel, Caino, M. Cecilia, and Altieri, Dario C.
- Published
- 2023
- Full Text
- View/download PDF
3. NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment
- Author
-
Bertolini, Irene, Perego, Michela, Ghosh, Jagadish C., Kossenkov, Andrew V., and Altieri, Dario C.
- Published
- 2022
- Full Text
- View/download PDF
4. Intercellular HIF1[alpha] reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions
- Author
-
Bertolini, Irene, Perego, Michela, Nefedova, Yulia, Lin, Cindy, Milcarek, Andrew, Vogel, Peter, Ghosh, Jagadish C., Kossenkov, Andrew V., and Altieri, Dario C.
- Subjects
T cells -- Health aspects ,Cell differentiation -- Health aspects ,Breast cancer -- Diagnosis -- Care and treatment ,Health care industry - Abstract
The origin of breast cancer, whether primary or recurrent, is unknown. Here, we show that invasive breast cancer cells exposed to hypoxia release small extracellular vesicles (sEVs) that disrupt the differentiation of normal mammary epithelia, expand stem and luminal progenitor cells, and induce atypical ductal hyperplasia and intraepithelial neoplasia. This was accompanied by systemic immunosuppression with increased myeloid cell release of the alarmin S100A9 and oncogenic traits of epithelial-mesenchymal transition, angiogenesis, and local and disseminated luminal cell invasion in vivo. In the presence of a mammary gland driver oncogene (MMTV-PyMT), hypoxic sEVs accelerated bilateral breast cancer onset and progression. Mechanistically, genetic or pharmacologic targeting of hypoxia-inducible factor-1[alpha] (HIF1[alpha]) packaged in hypoxic sEVs or homozygous deletion of S100A9 normalized mammary gland differentiation, restored T cell function, and prevented atypical hyperplasia. The transcriptome of sEV-induced mammary gland lesions resembled luminal breast cancer, and detection of HIF1[alpha] in plasma circulating sEVs from luminal breast cancer patients correlated with disease recurrence. Therefore, sEV-HIF1[alpha] signaling drives both local and systemic mechanisms of mammary gland transformation at high risk for evolution to multifocal breast cancer. This pathway may provide a readily accessible biomarker of luminal breast cancer progression., Introduction Breast cancer is the second most common malignancy diagnosed in women, resulting in over 43,000 deaths a year in the United States alone (1). Despite progress in early diagnosis [...]
- Published
- 2023
- Full Text
- View/download PDF
5. Editorial: Double-edged swords: important factors connecting metabolic disorders and cancer development -- from basic research to translational applications, volume II.
- Author
-
Che-Pei Kung, Barnoud, Thibaut, Cong-Hui Yao, Bertolini, Irene, and Murphy, Maureen E.
- Subjects
METABOLIC disorders ,CARCINOGENESIS ,TRANSLATIONAL research ,GLYCOLYSIS ,P-glycoprotein ,MOLECULAR biology ,RESPIRATION - Abstract
This document is an editorial published in Frontiers in Endocrinology titled "Double-edged swords: important factors connecting metabolic disorders and cancer development -- from basic research to translational applications, volume II." The editorial discusses the intersection between metabolic dysfunction and cancer development, highlighting new challenges and opportunities in this field. It covers various topics such as drug resistance in cancer therapy, strategies to overcome resistance in hepatocellular carcinoma, the role of immunity and metabolism in liver steatosis-driven carcinogenesis, the link between metabolic factors and thyroid cancer, the role of metabolites in kidney tubulogenesis, the role of glucose metabolism in human diseases, genetic alterations in metabolic enzymes and their contribution to diseases, the potential therapeutic target of MG53 in cancer, the potential of niclosamide in cancer therapy, and the role of innate immunity and inflammation in differential susceptibilities to metabolic disorders and cancer among racial populations. The editorial concludes by emphasizing the ongoing discussion and learning about the links between metabolic functions and cancer, from basic science to translational applications. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. The Communication of Extracellular Vesicles in Breast Cancer Progression
- Author
-
Bertolini, Irene
- Published
- 2020
- Full Text
- View/download PDF
7. Parkin ubiquitination of Kindlin-2 enables mitochondria-associated metastasis suppression.
- Author
-
Minjeong Yeon, Bertolini, Irene, Agarwal, Ekta, Ghosh, Jagadish C., Hsin-Yao Tang, Speicher, David W., Keeney, Frederick, Sossey-Alaoui, Khalid, Pluskota, Elzbieta, Bialkowska, Katarzyna, Plow, Edward F., Languino, Lucia R., Skordalakes, Emmanuel, Caino, M. Cecilia, and Altieri, Dario C.
- Subjects
- *
UBIQUITINATION , *PARKIN (Protein) , *FOCAL adhesions , *CELL motility , *CELL cycle , *PARKINSON'S disease , *MAMMARY glands - Abstract
Mitochondria are signaling organelles implicated in cancer, but the mechanisms are elusive. Here, we show that Parkin, an E3 ubiquitination (Ub) ligase altered in Parkinson's disease, forms a complex with the regulator of cell motility, Kindlin-2 (K2), at mitochondria of tumor cells. In turn, Parkin ubiquitinates Lys581 and Lys582 using Lys48 linkages, resulting in proteasomal degradation of K2 and shortened half-life from -5 h to -1.5 h. Loss of K2 inhibits focal adhesion turnover and ß1 integrin activation, impairs membrane lamellipodia size and frequency, and inhibits mitochondrial dynamics, altogether suppressing tumor cell-extracellular matrix interactions, migration, and invasion. Conversely, Parkin does not affect tumor cell proliferation, cell cycle transitions, or apoptosis. Expression of a Parkin Ub-resistant K2 Lys581Ala/Lys582Ala double mutant is sufficient to restore membrane lamellipodia dynamics, correct mitochondrial fusion/fission, and preserve single-cell migration and invasion. In a 3D model of mammary gland developmental morphogenesis, impaired K2 Ub drives multiple oncogenic traits of EMT, increased cell proliferation, reduced apoptosis, and disrupted basal-apical polarity. Therefore, deregulated K2 is a potent oncogene, and its Ub by Parkin enables mitochondria-associated metastasis suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
- Author
-
Formica, Miriam, Storaci, Alessandra Maria, Bertolini, Irene, Carminati, Francesca, Knævelsrud, Helene, Vaira, Valentina, and Vaccari, Thomas
- Subjects
TUMOR growth ,EPIDERMAL growth factor receptors ,AUTOPHAGY ,PHOSPHATIDYLINOSITOL 3-kinases ,DROSOPHILA ,MICROGLIA ,DROSOPHILA melanogaster ,DROSOPHILIDAE - Abstract
Glioblastoma (GBM), a very aggressive and incurable tumor, often results from constitutive activation of EGFR (epidermal growth factor receptor) and of phosphoinositide 3-kinase (PI3K). To understand the role of autophagy in the pathogenesis of glial tumors in vivo, we used an established Drosophila melanogaster model of glioma based on overexpression in larval glial cells of an active human EGFR and of the PI3K homolog Pi3K92E/Dp110. Interestingly, the resulting hyperplastic glia express high levels of key components of the lysosomal-autophagic compartment, including vacuolar-type H
+ -ATPase (V-ATPase) subunits and ref(2)P (refractory to Sigma P), the Drosophila homolog of SQSTM1/p62. However, cellular clearance of autophagic cargoes appears inhibited upstream of autophagosome formation. Remarkably, downregulation of subunits of V-ATPase, of Pdk1, or of the Tor (Target of rapamycin) complex 1 (TORC1) component raptor prevents overgrowth and normalize ref(2)P levels. In addition, downregulation of the V-ATPase subunit VhaPPA1-1 reduces Akt and Tor-dependent signaling and restores clearance. Consistent with evidence in flies, neurospheres from patients with high V-ATPase subunit expression show inhibition of autophagy. Altogether, our data suggest that autophagy is repressed during glial tumorigenesis and that V-ATPase and MTORC1 components acting at lysosomes could represent therapeutic targets against GBM. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells.
- Author
-
Li, Jie, Agarwal, Ekta, Bertolini, Irene, Seo, Jae Ho, Caino, M. Cecilia, Ghosh, Jagadish C., Kossenkov, Andrew V., Liu, Qin, Tang, Hsin-Yao, Goldman, Aaron R., Languino, Lucia R., Speicher, David W., and Altieri, Dario C.
- Subjects
CANCER cells ,CANCER cell proliferation ,ADENOSINE triphosphatase ,BIOENERGETICS ,EUKARYOTIC cells ,MITOCHONDRIAL membranes - Abstract
Suppressing metastasis for proliferation: Cancer cells must halt proliferative pathways and reprogram their morphology and metabolism to metastasize from the primary tumor. Li et al. found that FUNDC1 played a role in suppressing the switch from proliferation to metastasis in cancer cells of different tissue origins. In mice, xenografts formed from FUNDC1-deficient cancer cells developed into smaller primary tumors but were more likely to metastasize. FUNDC1 promoted proliferation by suppressing fission and relocalization of mitochondria to the leading edge of migrating cancer cells, enhancing oxidative metabolism, and limiting mitochondrial ROS production. These effects required the stabilization of the mitochondrial protease LonP1 and components of the mitochondrial ATP synthase complex (also known as complex V) by FUNDC1. By regulating mitochondrial morphology, localization, and function, FUNDC1 confers the cellular and metabolic features that support cancer cell proliferation. Mitochondria are signaling hubs in eukaryotic cells. Here, we showed that the mitochondrial FUN14 domain–containing protein-1 (FUNDC1), an effector of Parkin-independent mitophagy, also participates in cellular plasticity by sustaining oxidative bioenergetics, buffering ROS production, and supporting cell proliferation. Targeting this pathway in cancer cells suppressed tumor growth but rendered transformed cells more motile and invasive in a manner dependent on ROS-mediated mitochondrial dynamics and mitochondrial repositioning to the cortical cytoskeleton. Global metabolomics and proteomics profiling identified a FUNDC1 interactome at the mitochondrial inner membrane, comprising the AAA+ protease, LonP1, and subunits of oxidative phosphorylation, complex V (ATP synthase). Independently of its previously identified role in mitophagy, FUNDC1 enabled LonP1 proteostasis, which in turn preserved complex V function and decreased ROS generation. Therefore, mitochondrial reprogramming by a FUNDC1-LonP1 axis controls tumor cell plasticity by switching between proliferative and invasive states in cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α-regulated pseudohypoxic state.
- Author
-
Yuan Wang, Agarwal, Ekta, Bertolini, Irene, Ghosh, Jagadish C., Jae Ho Seo, and Altieri, Dario C.
- Published
- 2019
- Full Text
- View/download PDF
11. Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.
- Author
-
Agarwal, Ekta, Altman, Brian J., Jae Ho Seo, Bertolini, Irene, Ghosh, Jagadish C., Kaur, Amanpreet, Kossenkov, Andrew V., Languino, Lucia R., Gabrilovich, Dmitry I., Speicher, David W., Dang, Chi V., and Altieri, Dario C.
- Subjects
TRAFFIC engineering ,MYC oncogenes ,CELL motility ,ADAPTOR proteins ,METASTASIS ,CHEMOTAXIS - Abstract
The Myc gene is a universal oncogene that promotes aggressive cancer, but its role in metastasis has remained elusive. Here, we show that Myc transcriptionally controls a gene network of subcellular mitochondrial trafficking that includes the atypical mitochondrial GTPases RHOT1 and RHOT2, the adapter protein TRAK2, the anterograde motor Kif5B, and an effector of mitochondrial fission, Drp1. Interference with this pathway deregulates mitochondrial dynamics, shuts off subcellular organelle movements, and prevents the recruitment of mitochondria to the cortical cytoskeleton of tumor cells. In turn, this inhibits tumor chemotaxis, blocks cell invasion, and prevents metastatic spreading in preclinical models. Therefore, Myc regulation of mitochondrial trafficking enables tumor cell motility and metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment.
- Author
-
Bertolini, Irene, Ghosh, Jagadish C., Kossenkov, Andrew V., Mulugu, Sudheer, Krishn, Shiv Ram, Vaira, Valentina, Qin, Jun, Plow, Edward F., Languino, Lucia R., and Altieri, Dario C.
- Subjects
- *
EXTRACELLULAR vesicles , *TUMOR microenvironment , *CARCINOMA , *CELL migration , *EPITHELIAL-mesenchymal transition , *EXOSOMES , *MAMMARY glands - Abstract
The crosstalk between tumor cells and the adjacent normal epithelium contributes to cancer progression, but its regulators have remained elusive. Here, we show that breast cancer cells maintained in hypoxia release small extracellular vesicles (sEVs) that activate mitochondrial dynamics, stimulate mitochondrial movements, and promote organelle accumulation at the cortical cytoskeleton in normal mammary epithelial cells. This results in AKT serine/threonine kinase (Akt) activation, membrane focal adhesion turnover, and increased epithelial cell migration. RNA sequencing profiling identified integrin-linked kinase (ILK) as the most upregulated pathway in sEV-treated epithelial cells, and genetic or pharmacologic targeting of ILK reversed mitochondrial reprogramming and suppressed sEV-induced cell movements. In a three-dimensional (3D) model of mammary gland morphogenesis, sEV treatment induced hallmarks of malignant transformation, with deregulated cell death and/or cell proliferation, loss of apical-basal polarity, and appearance of epithelial-to-mesenchymal transition (EMT) markers. Therefore, sEVs released by hypoxic breast cancer cells reprogram mitochondrial dynamics and induce oncogenic changes in a normal mammary epithelium. • Hypoxic breast cancer cells release signaling sEVs • sEVs activate mitochondrial dynamics in recipient normal mammary epithelium • Mitochondrial reprogramming stimulates ILK-Akt-dependent epithelial cell migration • sEVs disrupt normal mammary gland morphogenesis with hallmarks of malignancy The communication between tumor cells and their neighbors is important for disease progression. Here, Bertolini et al. show that hypoxic breast cancer cells release small extracellular vesicles that introduce multiple malignant changes in the normal mammary epithelium via reprogramming of mitochondrial functions. This pathway may promote local breast cancer recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming.
- Author
-
Chae, Young Chan, Vaira, Valentina, Caino, M. Cecilia, Tang, Hsin-Yao, Seo, Jae Ho, Kossenkov, Andrew V., Ottobrini, Luisa, Martelli, Cristina, Lucignani, Giovanni, Bertolini, Irene, Locatelli, Marco, Bryant, Kelly G., Ghosh, Jagadish C., Lisanti, Sofia, Ku, Bonsu, Bosari, Silvano, Languino, Lucia R., Speicher, David W., and Altieri, Dario C.
- Subjects
- *
HYPOXEMIA , *PYRUVATE dehydrogenase kinase , *PYRUVATE dehydrogenase complex , *AUTOPHAGY , *CELL proliferation , *METABOLISM , *MITOCHONDRIA , *TUMORS - Abstract
Summary Hypoxia is a universal driver of aggressive tumor behavior, but the underlying mechanisms are not completely understood. Using a phosphoproteomics screen, we now show that active Akt accumulates in the mitochondria during hypoxia and phosphorylates pyruvate dehydrogenase kinase 1 (PDK1) on Thr346 to inactivate the pyruvate dehydrogenase complex. In turn, this pathway switches tumor metabolism toward glycolysis, antagonizes apoptosis and autophagy, dampens oxidative stress, and maintains tumor cell proliferation in the face of severe hypoxia. Mitochondrial Akt-PDK1 signaling correlates with unfavorable prognostic markers and shorter survival in glioma patients and may provide an “actionable” therapeutic target in cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.